AVEO Pharmaceuticals is a biopharmaceutical company. The company's product candidates include: tivozanib, its key candidate, a vascular endothelial growth factor receptor tyrosine kinase inhibitor which has been investigated in several tumor types, including renal cell, hepatocellular, colorectal and breast cancers; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is being tested for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; AV-203, an anti-ErbB3 specific monoclonal antibody with high ErbB3 affinity; and AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia.

Conn's is a holding company. Through its subsidiaries, the company is a retailer that provides consumer goods and related services in addition to proprietary credit solutions for its credit-constrained consumers. The company operates through its retail stores and website. The company's product offerings include furniture and mattresses, home appliances, consumer electronics and home office products. The company's credit offering provides financing solutions to credit-constrained consumers who typically have limited credit alternatives. The company's segments are: retail, which includes furniture and mattress, home appliance, consumer electronics, and home office; and credit, which provides standardized credit decisions.

New Media Investment Group owns, operates and invests in local media assets focused in small to mid-size markets. The company's main products include: daily newspapers; weekly newspapers, which publishe up to three times per week; shoppers, which are generally advertising-only publications; locally-focused websites, which extend the company's businesses onto the internet and mobile devices; business publications; UpCurve Cloud and ThriveHive digital marketing; and GateHouse Live. In addition to its main products, the company also produces publications that address specific local market interests such as recreation, sports, healthcare and real estate.

Harvest Capital Credit is an externally managed, closed-end, non-diversified management investment company. The company's investment objective is to generate both income and capital appreciation primarily by making direct investments in the form of subordinated debt, senior debt, and to a lesser extent, minority equity investments in privately-held United States small to mid-sized companies.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. The company's U.S. Food and Drug Administration approved commercial product, NUZYRA? (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA? (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris.

Snap is a camera company. The company's primary product, Snapchat, is a camera application that helps people to communicate visually through short videos and images called Snaps. The company's products are: Camera, which includes tools for people to personalize their Snaps; Chat, which includes interacting with friends on Snapchat; Discover, which includes providing Stories and Shows from publishers, creators, and the community; Snap Map, which shows a live map of the user's location; Memories, which enables users to save the Snaps they create in a personal collection called Memories; and Spectacles, which includes creating Memories by using Spectacles, which are the company's sunglasses that make Snaps.